Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that developed SKYCLARYS, the first FDA-approved treatment for Friedreich's ataxia, using its proprietary Nrf2 agonist platform. Acquired by Biogen in 2023 for approximately $7.3 billion following its February 2023 product launch.
- Company typePublic
- Founded2002
- HeadquartersIrving, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Reata Pharmaceuticals does
Reata Pharmaceuticals is a biopharmaceutical company founded in 2002 and headquartered in Irving, Texas, that developed novel therapeutics for serious diseases with significant unmet medical needs. Its core asset, SKYCLARYS (omaveloxolone), is an oral small molecule that received FDA approval in February 2023 as the first and only treatment for Friedreich's ataxia, a rare progressive neurodegenerative disease affecting coordination, muscle function, and cardiac health. The product was enabled by Reata's proprietary Nrf2 agonist platform, which produced a therapy addressing an indication with no previously approved disease-modifying options in the United States. SKYCLARYS was approved for patients aged 16 and older and distributed through specialty pharmacies serving the rare neurological disease patient population.
The company was publicly traded on NASDAQ under the ticker RETA and operated with 251–500 employees. Beyond SKYCLARYS, Reata had historically pursued bardoxolone methyl for multiple indications, but discontinued its chronic kidney disease (CKD) programs in Q1 2023 following trial results, narrowing strategic focus to the neurology franchise. The company secured a $275 million debt facility in Q1 2023 to extend its cash runway through 2026, providing optionality ahead of its next strategic move.
In July 2023, Biogen Inc. announced a definitive agreement to acquire Reata for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The transaction, which closed in Q3 2023, was motivated by Biogen's intent to expand its rare neurological disease portfolio and was followed by Reata being absorbed into Biogen's operations as a wholly-owned subsidiary.
Reata Pharmaceuticals firmographics
Firmographics- Name
- Reata Pharmaceuticals
- Legal name
- Reata Pharmaceuticals, Inc.
- Website
- https://reatapharma.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- Reata Pharmaceuticals is a biopharmaceutical company that developed SKYCLARYS, the first FDA-approved treatment for Friedreich's ataxia, using its proprietary Nrf2 agonist platform. Acquired by Biogen in 2023 for approximately $7.3 billion following its February 2023 product launch.
- Ownership category
- akta.pro rank
Reata Pharmaceuticals industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI), Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Reata Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Irving
- HQ country
- United States
- HQ region
- North America
Markets served
Reata Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Reata Pharmaceuticals product offering
Product offeringCore offering
Reata Pharmaceuticals developed and commercialized SKYCLARYS (omaveloxolone), the first and only FDA-approved oral treatment for Friedreich's ataxia in patients aged 16 and older in the United States. The company also developed bardoxolone methyl for chronic kidney disease indications, though CKD programs were discontinued in 2023. Reata operated as a specialty biopharmaceutical company focused on novel small molecule therapeutics for serious diseases with significant unmet medical need.
Product overview
Reata Pharmaceuticals operated as a biopharmaceutical company focused on developing novel therapeutics for severe diseases with significant unmet medical needs. The company's primary product portfolio centered on SKYCLARYS, an FDA-approved oral treatment for Friedreich's ataxia. The company also developed bardoxolone methyl (bardoxolone) for various indications, though CKD programs were discontinued following trial results. Reata Pharmaceuticals was acquired by Biogen in 2023.
Differentiator
Problem solved
Functional benefit
Brands
- SKYCLARYS: FDA-approved treatment for Friedreich's ataxia, the first and only treatment for this rare neurological disease in the United States.
Products and services
- SKYCLARYS (omaveloxolone) SKYCLARYS is an FDA-approved oral small molecule drug for the treatment of Friedreich's ataxia in patients 16 years of age and older. It is the first and only approved therapy specifically for this rare neuromuscular disorder in the United States, addressing a previously unmet medical need.
Quantifiable outcome
- FDA approval obtained February 2023 for SKYCLARYS
Companies that use Reata Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Reata Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Reata Pharmaceuticals partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights3 records
Reata Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Design Therapeutics: Early-stage biotech developing genomic medicines for serious nucleotide-repeat diseases including Friedreich's ataxia. Emerging competitive threat in Reata's primary indication.
- SAGE Therapeutics: Specialty biopharma focused on CNS disorders with approved rare-epilepsy therapy. Similar model of small molecule neurology development in underserved indications.
Broad incumbents
- Alexion / AstraZeneca Rare Disease: Established rare disease unit within AstraZeneca with multiple orphan-drug franchises in neurology, hematology, and metabolic disease. Provides broader commercialization scale comparable to Biogen's acquisition rationale for Reata.
- Vertex Pharmaceuticals: Large-cap biopharma with deep rare-disease franchise (cystic fibrosis, sickle cell) and growing rare neurology pipeline. Broader incumbent operating across multiple rare disease verticals.
Direct peers
- Larimar Therapeutics: Clinical-stage biopharmaceutical company developing treatments specifically for Friedreich's ataxia. Directly competes with SKYCLARYS in the same indication and patient population.
- PTC Therapeutics: Develops vatiquinone and other candidates for Friedreich's ataxia and other rare neurological/mitochondrial disorders. Directly comparable to Reata in the Friedreich's ataxia competitive landscape.
- BioMarin Pharmaceutical: Specialty biopharma focused exclusively on rare diseases with multiple orphan-drug approvals. Closely aligned with Reata's business model of developing and commercializing treatments for ultra-rare conditions.
- Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with multiple approved products across metabolic, neurological, and other orphan indications. Comparable model of single-platform rare disease development and commercialization.
- Sarepta Therapeutics: Specialty biopharma focused on rare neuromuscular and neurological genetic diseases with multiple approved RNA-based therapies. Closely aligned with Reata's rare neurodegenerative focus.
- Ionis Pharmaceuticals: Develops RNA-targeted therapeutics for serious and rare neurological, neuromuscular, and metabolic diseases. Comparable specialty pharma approach in rare neurological disorders.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights3 records
Customer concentration
Reata Pharmaceuticals social profiles
Digital presenceReata Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reata Pharmaceuticals leadership team
Management profileNumber of profiles
Reata Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds16 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reata Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reata Pharmaceuticals
What does Reata Pharmaceuticals do?
Reata Pharmaceuticals developed and commercialized SKYCLARYS (omaveloxolone), the first and only FDA-approved oral treatment for Friedreich's ataxia in patients aged 16 and older in the United States. The company also developed bardoxolone methyl for chronic kidney disease indications, though CKD programs were discontinued in 2023. Reata operated as a specialty biopharmaceutical company focused on novel small molecule therapeutics for serious diseases with significant unmet medical need.
Is Reata Pharmaceuticals a public or private company?
Reata Pharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.
When was Reata Pharmaceuticals founded?
Reata Pharmaceuticals was founded in 2002. It employs 251 to 500 people.
Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals is headquartered in Irving, United States, in the North America region.
Who are Reata Pharmaceuticals's main competitors?
Emerging players on record are Design Therapeutics and SAGE Therapeutics. Broad incumbents are Alexion / AstraZeneca Rare Disease and Vertex Pharmaceuticals. Direct peers are Larimar Therapeutics, PTC Therapeutics, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Sarepta Therapeutics and Ionis Pharmaceuticals.
Does Reata Pharmaceuticals have an API?
No public API is recorded for Reata Pharmaceuticals.
What industry is Reata Pharmaceuticals in?
Reata Pharmaceuticals's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.